Advertisement

Topics

Janssen And AbbVie Lymphoma Treatment Misses Primary Endpoint

07:06 EDT 13 Jul 2018 | Pharmaceutical Processing

The Phase 3 trial of Imbruvica did not meet the primary endpoint of event-free survival in patients with a subtype of diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma. Some further analyses will be conducted.
Staff Author: 

Original Article: Janssen And AbbVie Lymphoma Treatment Misses Primary Endpoint

NEXT ARTICLE

More From BioPortfolio on "Janssen And AbbVie Lymphoma Treatment Misses Primary Endpoint"

Advertisement
Quick Search
Advertisement
Advertisement